Coriolis PharmaService chooses NanoSight to study the aggregation of protein drugs and vaccines

Sponsors

Coriolis PharmaService chooses NanoSight to study the aggregation of protein drugs and vaccines

Salisbury, UK, 7th September 2010: - Munich-based company Coriolis PharmaServices GmbH is using NanoSight’s LM-20 nanoparticle characterization system to investigate the aggregation behaviour of protein drugs and vaccines.

Coriolis is a contract research organization for the formulation and analytics of pharmaceutical proteins and vaccines for their customers from national and international pharmaceutical companies. A special focus during formulation development is set on the characterization of subvisible particles and aggregation. The main application requirement for the NanoSight system is to measure the number and the size distribution of aggregates in pharmaceutical protein formulations and of vaccines, e.g. virus-like particles.

The NanoSight LM 20 system in use at Coriolis PharmaServices

Protein aggregation is a major stability issue and can result in reduced biological activity and enhanced immunogenicity of the product. Therefore, it is important to analyze the aggregation behaviour of pharmaceutical proteins and develop methods and formulations that avoid aggregation already at the beginning of formulation development.

Coriolis uses a variety of instrumental techniques to quantify and size aggregates, depending on the size range of interest. Dynamic light scattering is ideal to analyze monodisperse systems, e.g. 5-20 nm range, but once the aggregates start to form and grow (in the hundreds of nm range), nanoparticle tracking analysis (NTA) from NanoSight gives a real distribution picture. For samples in the µm range, microflow imaging (MFI) and light obscuration are used.

In contrast to DLS, NTA works well with polydisperse samples giving an estimation of the total concentration of particles and the possibility to distinguish different size populations, e.g. 60 and 100 nm particles. This is not possible by DLS due to the poor resolution.

Speaking at the recent National Biotech Conference 2010 in San Francisco, the Coriolis team under Dr Michael Wiggenhorn reported that to achieve a comprehensive characterization of nanoscale particulates in protein formulations, it is important to combine techniques that operate in that range. However, the ability of NTA to provide a real-time image of samples permits the analysis of potentially occurring difficulties during the measurement which is not possible using DLS.

To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis, NTA, please visit the company website and register for the latest issue of NanoTrail, the company’s electronic newsletter. For more about Coriolis, please see their website.

For further information
Please contact NanoSight direct or their marketing agency, NetDyaLog Limited:

NanoSight Limited
Minton Park
London Road
Amesbury SP4 7RT
T +44 (0) 1980 676060
F +44 (0) 1980 624703
www.nanosight.com
jeremy.warren@nanosight.com

NetDyaLog Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA
T +44 (0) 1799 521881
M +44 (0) 7843 012997
www.netdyalog.com
jezz@netdyalog.com

generate PDF File

More News:
» Phenom-World is launching the Phenom Programming Interface (PPI) for the Phenom™ desktop scanning electron microscope
» Xmark Media, in association with Imperial College, announces Photonex London- photonics technology roadshow: the first in a series of FREE regional events focusing on applications of photonics
» Linkam temperature controlled probe stage used in conjunction with Raman microscopy at RMIT, Melbourne, Australia
» Sharp live images from the mouse brain
» Mac microscopy software looking for interested hardware vendors

Home

Contact

Imprint

Sitemap